Dick de Zeeuw

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8825162/publications.pdf

Version: 2024-02-01

567	64,589	1883	890
papers	citations	102 h-index	242 g-index

584	584	584	35299
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2001, 345, 861-869.	13.9	6,609
2	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 644-657.	13.9	5,629
3	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	13.9	3,760
4	Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 2005, 67, 2089-2100.	2.6	2,836
5	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2009, 361, 2019-2032.	13.9	2,110
6	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	6.3	2,087
7	Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population. Circulation, 2002, 106, 1777-1782.	1.6	1,395
8	Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. New England Journal of Medicine, 2012, 367, 2204-2213.	13.9	1,145
9	Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. Annals of Internal Medicine, 2003, 139, 244.	2.0	945
10	Renal Function, Neurohormonal Activation, and Survival in Patients With Chronic Heart Failure. Circulation, 2000, 102, 203-210.	1.6	935
11	Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. Annals of Internal Medicine, 2001, 135, 73.	2.0	927
12	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2492-2503.	13.9	844
13	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney International, 2004, 65, 2309-2320.	2.6	842
14	Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney International, 2004, 65, 1416-1421.	2.6	836
15	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation, 2006, 113, 671-678.	1.6	817
16	Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy. Circulation, 2004, 110, 921-927.	1.6	679
17	Dapagliflozin a glucoseâ€regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 2013, 15, 853-862.	2.2	658
18	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet, The, 2010, 376, 1543-1551.	6.3	613

#	Article	IF	Citations
19	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 2011, 79, 1331-1340.	2.6	609
20	Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. Journal of Internal Medicine, 2001, 249, 519-526.	2.7	547
21	Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria. Circulation, 2004, 110, 2809-2816.	1.6	489
22	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2018, 6, 691-704.	5.5	460
23	The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney International, 2003, 63, 1499-1507.	2.6	456
24	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 1146-1155.	13.9	433
25	GFR Decline as an End Point for Clinical Trials in CKD: AÂScientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. American Journal of Kidney Diseases, 2014, 64, 821-835.	2.1	430
26	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	6.3	414
27	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	6.3	408
28	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation, 2018, 137, 323-334.	1.6	393
29	Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2009, 373, 1009-1015.	6.3	384
30	Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation, 2018, 138, 458-468.	1.6	370
31	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney International, 2001, 60, 1131-1140.	2.6	334
32	Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney International, 1989, 36, 272-279.	2.6	332
33	Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan. Journal of the American Society of Nephrology: JASN, 2008, 19, 999-1007.	3.0	330
34	Microalbuminuria as an Early Marker for Cardiovascular Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2100-2105.	3.0	319
35	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. American Journal of Kidney Diseases, 2020, 75, 84-104.	2.1	311
36	A central body fat distribution is related to renal function impairment, even in lean subjects. American Journal of Kidney Diseases, 2003, 41, 733-741.	2.1	309

#	Article	IF	Citations
37	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)â€"A randomized placebo-controlled trial. American Heart Journal, 2013, 166, 217-223.e11.	1.2	290
38	The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. Journal of Internal Medicine, 2004, 256, 1-14.	2.7	289
39	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation, 2009, 24, 1663-1671.	0.4	286
40	An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney International, 2011, 80, 282-287.	2.6	282
41	Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. Journal of the American Society of Nephrology: JASN, 2007, 18, 1540-1546.	3.0	280
42	Urinary Albumin Excretion Is Associated with Renal Functional Abnormalities in a Nondiabetic Population. Journal of the American Society of Nephrology: JASN, 2000, 11, 1882-1888.	3.0	276
43	Is the antiproteinuric effect of ACE inhibition mediated by intereference in the renin-angiotensin system?. Kidney International, 1994, 45, 861-867.	2.6	264
44	Smoking Is Related to Albuminuria and Abnormal Renal Function in Nondiabetic Persons. Annals of Internal Medicine, 2000, 133, 585.	2.0	229
45	First Morning Voids Are More Reliable Than Spot Urine Samples to Assess Microalbuminuria. Journal of the American Society of Nephrology: JASN, 2009, 20, 436-443.	3.0	225
46	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	5.5	223
47	The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1083-1093.	3.0	222
48	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 687-696.	5.5	221
49	Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. European Heart Journal, 2018, 39, 1535-1542.	1.0	218
50	Albuminuria Assessed From First-Morning-Void Urine Samples Versus 24-Hour Urine Collections as a Predictor of Cardiovascular Morbidity and Mortality. American Journal of Epidemiology, 2008, 168, 897-905.	1.6	215
51	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
52	C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney International, 2003, 63, 654-661.	2.6	208
53	Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney International, 2012, 82, 330-337.	2.6	204
54	Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection. Journal of the American Society of Nephrology: JASN, 2015, 26, 2055-2064.	3.0	204

#	Article	IF	Citations
55	Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney International, 1987, 32, 78-83.	2.6	201
56	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation, 2018, 138, 1537-1550.	1.6	200
57	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	5.5	199
58	Efficacy and Safety of Canagliflozin, an Inhibitor of Sodiumâ€“Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 403-411.	4.3	196
59	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, 2017, 46, 462-472.	1.4	194
60	Sodium intake affects urinary albumin excretion especially in overweight subjects. Journal of Internal Medicine, 2004, 256, 324-330.	2.7	187
61	A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney International, 1997, 51, 793-797.	2.6	180
62	Macroalbuminuria Is a Better Risk Marker than Low Estimated GFR to Identify Individuals at Risk for Accelerated GFR Loss in Population Screening. Journal of the American Society of Nephrology: JASN, 2006, 17, 2582-2590.	3.0	176
63	Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency) Tj ETQq1 1 0.784314 rgBT /Overlock	3.1	172
64	Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 761-767.	2.2	171
65	Angiotensin-(1â€“7) Is a Modulator of the Human Renin-Angiotensin System. Hypertension, 1999, 34, 296-301.	1.3	164
66	Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment. Hypertension, 2011, 58, 2-7.	1.3	164
67	Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet, The, 1996, 347, 94-95.	6.3	163
68	Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrology Dialysis Transplantation, 1995, 10, 497-504.	0.4	161
69	Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrology Dialysis Transplantation, 2008, 23, 3851-3858.	0.4	156
70	An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney International, 2004, 66, S18-S21.	2.6	155
71	Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1959-1965.	3.0	154
72	Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney International, 2002, 62, 1020-1025.	2.6	152

#	Article	IF	Citations
73	Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 123-130.	3.0	151
74	Comparison of Different Measures of Urinary Protein Excretion for Prediction of Renal Events. Journal of the American Society of Nephrology: JASN, 2010, 21, 1355-1360.	3.0	144
75	The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrology Dialysis Transplantation, 2003, 18, 2047-2053.	0.4	143
76	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 1825-1833.	3.0	142
77	Angiotensin Converting Enzyme Inhibitors and Progressive Renal Insufficiency. Annals of Internal Medicine, 1989, 111, 503.	2.0	141
78	Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. Journal of Cardiac Failure, 2014, 20, 953-958.	0.7	139
79	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Studyâ€“Renal (<scp>CANVASâ€R</scp>): A randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 387-393.	2.2	139
80	Excessive Urinary Albumin Levels Are Associated With Future Cardiovascular Mortality in Postmenopausal Women. Circulation, 2001, 103, 3057-3061.	1.6	135
81	Screening for Albuminuria Identifies Individuals at Increased Renal Risk. Journal of the American Society of Nephrology: JASN, 2009, 20, 852-862.	3.0	133
82	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	6.3	133
83	The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney International, 2005, 67, S28-S35.	2.6	132
84	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia, 2013, 56, 259-267.	2.9	128
85	The effect of RAAS blockade on the progression of diabetic nephropathy. Nature Reviews Nephrology, 2014, 10, 77-87.	4.1	128
86	The glycocalyxâ€"linking albuminuria with renal and cardiovascular disease. Nature Reviews Nephrology, 2015, 11, 667-676.	4.1	128
87	Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2591-2593.	1.6	121
88	Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with TypeÂ2 diabetes mellitus. Diabetic Medicine, 2014, 31, 1138-1147.	1.2	119
89	The losartan renal protection study â€" rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 328-335.	1.0	118
90	Urinary Albumin Excretion and Its Relation With C-Reactive Protein and the Metabolic Syndrome in the Prediction of Type 2 Diabetes. Diabetes Care, 2005, 28, 2525-2530.	4.3	118

#	Article	IF	Citations
91	Rationaleâ€"Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal, 2005, 149, 408-413.	1.2	115
92	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. European Heart Journal, 2011, 32, 1493-1499.	1.0	115
93	Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. Journal of Psychosomatic Research, 2014, 76, 134-138.	1.2	115
94	Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 181-190.	5.5	114
95	Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results. Journal of the American Society of Nephrology: JASN, 2004, 15, 3117-3125.	3.0	112
96	Gender differences in predictors of the decline of renal function in the general population. Kidney International, 2008, 74, 505-512.	2.6	112
97	Cardiovascular Risk Factors Are Differently Associated with Urinary Albumin Excretion in Men and Women. Journal of the American Society of Nephrology: JASN, 2003, 14, 1330-1335.	3.0	110
98	Urinary Albumin Excretion as a Predictor of the Development of Hypertension in the General Population. Journal of the American Society of Nephrology: JASN, 2006, 17, 331-335.	3.0	107
99	Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2011, 58, 729-736.	2.1	107
100	Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. American Journal of Nephrology, 2014, 40, 64-74.	1.4	106
101	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1128-1139.	3.0	106
102	N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. European Heart Journal, 2010, 31, 120-127.	1.0	103
103	Renoprotective therapy: titration against urinary protein excretion. Lancet, The, 1999, 354, 352-353.	6.3	102
104	Long-Term Benefits of the Antiproteinuric Effect of Angiotensin-Converting Enzyme Inhibition in Nondiabetic Renal Disease. American Journal of Kidney Diseases, 1993, 22, 202-206.	2.1	99
105	Atrial natriuretic factor: Its (patho)physiological significance in humans. Kidney International, 1992, 41, 1115-1133.	2.6	95
106	The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney International, 2005, 68, S25-S29.	2.6	95
107	Microalbuminuria and Endothelial Dysfunction: Emerging Targets for Primary Prevention of End-organ Damage. Journal of Cardiovascular Pharmacology, 2006, 47, S151-S162.	0.8	95
108	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%. Circulation, 2020, 141, 407-410.	1.6	95

#	Article	IF	Citations
109	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia, 2019, 62, 926-938.	2.9	94
110	Review: Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review. Medical Care Research and Review, 2011, 68, 263-289.	1.0	93
111	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2019, 30, 2229-2242.	3.0	93
112	Mediators of the Effects of Canagliflozin on HeartÂFailure in Patients With Type 2 Diabetes. JACC: Heart Failure, 2020, 8, 57-66.	1.9	93
113	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, 2021, 99, 999-1009.	2.6	93
114	Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney International, 2006, 69, 1675-1682.	2.6	92
115	Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Hypertension, and Renal Disease. Diabetes Care, 2004, 27, 1897-1903.	4.3	91
116	Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia, 2011, 54, 44-50.	2.9	91
117	Optimizing the analysis strategy for the <scp>CANVAS</scp> Program: A prespecified plan for the integrated analyses of the <scp>CANVAS</scp> and <scp>CANVASâ€R</scp> trials. Diabetes, Obesity and Metabolism, 2017, 19, 926-935.	2.2	89
118	Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase?. Nephrology Dialysis Transplantation, 2003, 18, 10-13.	0.4	88
119	The albuminuriaâ€lowering response to dapagliflozin is variable and reproducible among individual patients. Diabetes, Obesity and Metabolism, 2017, 19, 1363-1370.	2.2	88
120	The association between atherosclerotic risk factors and renal function in the general population. Kidney International, 2005, 67, 1967-1973.	2.6	87
121	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1705-1714.	2.2	87
122	Prevention of chronic kidney and vascular disease: Toward global health equityâ€”The Bellagio 2004 Declaration. Kidney International, 2005, 68, S1-S6.	2.6	86
123	C-Reactive Protein Modifies the Relationship Between Blood Pressure and Microalbuminuria. Hypertension, 2004, 43, 791-796.	1.3	84
124	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). American Journal of Nephrology, 2013, 37, 212-222.	1.4	82
125	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 2925-2936.	3.0	82
126	Impact of weight change on albuminuria in the general population. Nephrology Dialysis Transplantation, 2007, 22, 1619-1627.	0.4	81

#	Article	IF	Citations
127	ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy. Journal of the American Society of Nephrology: JASN, 2008, 19, 771-779.	3.0	80
128	Albuminuria, Estimated GFR, Traditional Risk Factors, and Incident Cardiovascular Disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) Study. American Journal of Kidney Diseases, 2012, 60, 804-811.	2.1	79
129	Myocardial Infarction Enhances Progressive Renal Damage in an Experimental Model for Cardio-Renal Interaction. Journal of the American Society of Nephrology: JASN, 2004, 15, 3103-3110.	3.0	78
130	Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. Kidney International, 2004, 66, S2-S6.	2.6	78
131	Effects of nonsteroidal anti-inflammatory drugs on proteinuria. American Journal of Medicine, 1986, 81, 84-94.	0.6	77
132	Extended Prognostic Value of Urinary Albumin Excretion for Cardiovascular Events. Journal of the American Society of Nephrology: JASN, 2008, 19, 1785-1791.	3.0	76
133	High Protein Intake Associates with Cardiovascular Events but not with Loss of Renal Function. Journal of the American Society of Nephrology: JASN, 2009, 20, 1797-1804.	3.0	75
134	Efficacy and safety of canagliflozin when used in conjunction with incretinâ€mimetic therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 82-91.	2.2	74
135	Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). American Heart Journal, 2011, 162, 748-755.e3.	1.2	72
136	ACE Inhibitors and the Kidney. Drug Safety, 1996, 15, 200-211.	1.4	70
137	Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney International, 2014, 86, 819-827.	2.6	70
138	Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 2225-2233.	3.0	69
139	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney International, 2020, 98, 769-777.	2.6	69
140	Antiproteinuric Effect Predicts Renal Protection by Angiotensin-Converting Enzyme Inhibition in Rats with Established Adriamycin Nephrosis. Clinical Science, 1996, 90, 393-401.	1.8	68
141	Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 66-73.	2.2	67
142	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrology Dialysis Transplantation, 2017, 32, gfw292.	0.4	66
143	The Kidney in Type 2 Diabetes Therapy. Review of Diabetic Studies, 2011, 8, 392-402.	0.5	66
144	Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Current Opinion in Nephrology and Hypertension, 2006, 15, 631-636.	1.0	65

#	Article	IF	Citations
145	Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy. Seminars in Nephrology, 2007, 27, 172-181.	0.6	65
146	Microalbuminuria: target for renoprotective therapy PRO. Kidney International, 2014, 86, 40-49.	2.6	65
147	Visit-to-Visit Variability in Blood Pressure and Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Nephropathy: A Post Hoc Analysis From the RENAAL Study and the Irbesartan Diabetic Nephropathy Trial. American Journal of Kidney Diseases, 2014, 64, 714-722.	2.1	65
148	International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.	2.6	65
149	Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. British Journal of Pharmacology, 2000, 130, 1999-2007.	2.7	63
150	Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. Kidney International, 2004, 66, S69-S75.	2.6	63
151	Low-molecular-weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. Journal of Medicinal Chemistry, 1992, 35, 1246-1259.	2.9	61
152	Enhanced Responses of Blood Pressure, Renal Function, and Aldosterone to Angiotensin I in the DD Genotype Are Blunted by Low Sodium Intake. Journal of the American Society of Nephrology: JASN, 2002, 13, 1025-1033.	3.0	61
153	Role of elevated lecithin: Cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. Kidney International, 1993, 44, 91-97.	2.6	60
154	Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2003, 139, 90.	2.0	60
155	Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrology Dialysis Transplantation, 2006, 22, 321-328.	0.4	60
156	Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2009, 54, 59-69.	2.1	60
157	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 2018, 20, 1369-1376.	2.2	60
158	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. Circulation, 2021, 143, 1735-1749.	1.6	60
159	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. Stroke, 2021, 52, 1545-1556.	1.0	60
160	Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney International, 1993, 44, 579-584.	2.6	59
161	Falsely Low Urinary Albumin Concentrations after Prolonged Frozen Storage of Urine Samples. Clinical Chemistry, 2005, 51, 2181-2183.	1.5	59
162	Validity of biomarkers predicting onset or progression of nephropathy in patients with Typeâ€ƒ2 diabetes: a systematic review. Diabetic Medicine, 2012, 29, 567-577.	1.2	59

#	Article	IF	Citations
163	Early reninâ€angiotensin system intervention is more beneficial than late intervention in delaying endâ€stage renal disease in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 64-71.	2.2	59
164	Moderate sodium restriction in hypertensive subjects: Renal effects of ACE-inhibition. Kidney International, 1987, 31, 815-819.	2.6	58
165	Initial Angiotensin Receptor Blockadeâ€"Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria. Diabetes Care, 2011, 34, 2078-2083.	4.3	58
166	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia, 2019, 62, 1854-1867.	2.9	58
167	Does the Renin-Angiotensin System Determine the Renal and Systemic Hemodynamic Response to Sodium in Patients With Essential Hypertension?. Hypertension, 1996, 27, 202-208.	1.3	58
168	Kinetically stable complexes of alkali cations with calixspherands: an evaluation of shielding. Journal of the American Chemical Society, 1994, 116, 123-133.	6.6	57
169	Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. American Heart Journal, 2004, 148, 165-172.	1.2	57
170	Bilirubin and Progression of Nephropathy in Type 2 Diabetes: A Post Hoc Analysis of RENAAL With Independent Replication in IDNT. Diabetes, 2014, 63, 2845-2853.	0.3	57
171	A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes. PLoS ONE, 2015, 10, e0120995.	1.1	57
172	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	2.1	57
173	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. American Journal of Kidney Diseases, 2018, 71, 91-101.	2.1	57
174	Drug-targeting to the kidney: Renal delivery and degradation of a naproxen-lysozyme conjugate in vivo. Kidney International, 1997, 52, 1693-1699.	2.6	56
175	Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 387-393.	1.0	56
176	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. Diabetes, Obesity and Metabolism, 2019, 21, 2368-2383.	2.2	56
177	LONG-TERM RENAL OUTCOME AFTER LUNG TRANSPLANTATION IS PREDICTED BY THE 1-MONTH POSTOPERATIVE RENAL FUNCTION LOSS. Transplantation, 2000, 69, 1624-1628.	0.5	56
178	The reliability of different formulae to predict creatinine clearance. Journal of Internal Medicine, 2003, 253, 563-573.	2.7	55
179	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney International, 2005, 67, S2-S7.	2.6	55
180	Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Nonâ€"Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). American Journal of Kidney Diseases, 2014, 63, 244-250.	2.1	55

#	Article	IF	Citations
181	Evaluation of Measures of Urinary Albumin Excretion. American Journal of Epidemiology, 2006, 164, 725-727.	1.6	54
182	Endothelial Dilatory Function Predicts Individual Susceptibility to Renal Damage in the 5/6 Nephrectomized Rat. Journal of the American Society of Nephrology: JASN, 2002, 13, 2909-2915.	3.0	53
183	Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2340-2346.	4.3	52
184	Diuretic Effects of Angiotensin-Converting Enzyme Inhibition. Journal of Cardiovascular Pharmacology, 1987, 9, 743-748.	0.8	51
185	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke, 2019, 50, 396-404.	1.0	51
186	Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition. Kidney International, 1991, 40, 734-741.	2.6	49
187	Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. Biomedical Applications, 1997, 693, 181-189.	1.7	49
188	A Longitudinal Study Examining Adherence to Guidelines in Diabetes Care According to Different Definitions of Adequacy and Timeliness. PLoS ONE, 2011, 6, e24278.	1.1	49
189	LDL cholesterol in CKDâ€"to treat or not to treat?. Kidney International, 2013, 84, 451-456.	2.6	49
190	Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the <scp>ALTITUDE</scp> trial. Diabetes, Obesity and Metabolism, 2016, 18, 169-177.	2.2	49
191	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases, 2019, 73, 206-217.	2.1	49
192	C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. Atherosclerosis, 2004, 172, 107-114.	0.4	48
193	Need for better diabetes treatment for improved renal outcome. Kidney International, 2011, 79, S28-S32.	2.6	48
194	Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. Journal of the American Society of Nephrology: JASN, 2004, 15, 1316-22.	3.0	48
195	Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. Pharmaceutical Research, 1991, 08, 1223-1230.	1.7	47
196	Low Levels of Urinary Albumin Excretion Are Associated with Cardiovascular Risk Factors in the General Population. Clinical Chemistry and Laboratory Medicine, 2000, 38, 1107-10.	1.4	46
197	Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. American Journal of Kidney Diseases, 2001, 38, 1381-1384.	2.1	46
198	Specific drug delivery to the kidney. Cardiovascular Drugs and Therapy, 2002, 16, 489-496.	1.3	44

#	Article	IF	Citations
199	Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade. British Journal of Pharmacology, 2003, 139, 1317-1325.	2.7	43
200	The role of angiotensin(1â€“7) in renal vasculature of the rat. Journal of Hypertension, 2006, 24, 1971-1978.	0.3	42
201	Monitoring Kidney Function and Albuminuria in Patients With Diabetes. Diabetes Care, 2011, 34, S325-S329.	4.3	42
202	New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney International, 2021, 99, 346-349.	2.6	42
203	Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrology Dialysis Transplantation, 2001, 16, 771-775.	0.4	41
204	Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia, 2005, 48, 1980-1987.	2.9	41
205	Apparent Loss of Urinary Albumin during Long-term Frozen Storage: HPLC vs Immunonephelometry. Clinical Chemistry, 2007, 53, 1520-1526.	1.5	41
206	Intracellular Angiotensin II and cell growth of vascular smooth muscle cells. British Journal of Pharmacology, 2001, 132, 1590-1596.	2.7	40
207	Unmet need in diabetic nephropathy: failed drugs or trials?. Lancet Diabetes and Endocrinology,the, 2016, 4, 638-640.	5.5	40
208	Systems Biologyâ€“Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes. Diabetes Care, 2017, 40, 391-397.	4.3	40
209	<scp>Sodiumâ€glucose coâ€transporterâ€2</scp> inhibitors with and without metformin: A metaâ€analysis of cardiovascular, kidney and mortality outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 382-390.	2.2	40
210	Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy. Hypertension, 2010, 55, 1206-1209.	1.3	39
211	Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 309-317.	5.5	39
212	ACE-inhibitors: panacea for progressive renal disease?. Lancet, The, 1997, 349, 1852-1853.	6.3	38
213	Composite renal endpoints: was ACCOMPLISH accomplished?. Lancet, The, 2010, 375, 1140-1142.	6.3	38
214	Novel drugs and intervention strategies for the treatment of chronic kidney disease. British Journal of Clinical Pharmacology, 2013, 76, 536-550.	1.1	38
215	The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatology, The, 2019, 1, e220-e228.	2.2	38
216	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. American Journal of Kidney Diseases, 2021, 77, 23-34.e1.	2.1	38

#	Article	IF	Citations
217	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney International, 2000, 57, S32-S37.	2.6	37
218	Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable?. Journal of Heart and Lung Transplantation, 2000, 19, 256-262.	0.3	37
219	Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrology Dialysis Transplantation, 2000, 15, 637-643.	0.4	37
220	Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney International, 2002, 62, 181-191.	2.6	37
221	Effect of First Myocardial Ischemic Event on Renal Function. American Journal of Cardiology, 2007, 100, 7-12.	0.7	37
222	The renal protective effect of angiotensin receptor blockers depends on intraâ€individual response variation in multiple risk markers. British Journal of Clinical Pharmacology, 2015, 80, 678-686.	1.1	37
223	Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 (Irbesartan Diabetic Nephropathy Trial). American Journal of Kidney Diseases, 2015, 66, 450-458.	2.1	37
224	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 384-395.	2.2	37
225	Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. Journal of Nephrology, 2006, 19, 246-58.	0.9	37
226	Trends in the incidence of treated end-stage renal failure in The Netherlands: Hope for the future?. Kidney International, 2004, 66, S7-S10.	2.6	36
227	Renoprotective effects of renin-angiotensin-system inhibitors. Lancet, The, 2006, 367, 899-900.	6.3	36
228	The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial. European Journal of Preventive Cardiology, 2014, 21, 299-309.	0.8	36
229	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy, 2015, 6, 289-302.	1.2	36
230	Î”9-Tetrahydrocannabinol activates [Ca2+]i increases partly sensitive to capacitative store refilling. European Journal of Pharmacology, 1997, 336, R1-R3.	1.7	35
231	What Predicts Progression and Regression of Urinary Albumin Excretion in the Nondiabetic Population?. Journal of the American Society of Nephrology: JASN, 2007, 18, 637-645.	3.0	35
232	Systemic gene therapy with interleukin-13 attenuates renal ischemiaâ€“reperfusion injury. Kidney International, 2008, 73, 1364-1373.	2.6	35
233	Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. Nephrology Dialysis Transplantation, 2008, 23, 3103-3110.	0.4	35
234	The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics. American Journal of Nephrology, 2009, 30, 280-286.	1.4	35

#	Article	IF	Citations
235	Debate: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial. American Journal of Nephrology, 2010, 31, 458-461.	1.4	35
236	Systemic Factors Are Involved in the Pathogenesis of Proteinuria-Induced Glomerulosclerosis in Adriamycin Nephrotic Rats. Journal of the American Society of Nephrology: JASN, 1999, 10, 2359-2366.	3.0	35
237	The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. Journal of Hypertension, 2005, 23, 2055-2061.	0.3	34
238	NTâ€proBNP by Itself Predicts Death and Cardiovascular Events in Highâ€Risk Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e017462.	1.6	34
239	Antiproteinuric Effect of Naproxen and Indomethacin. American Journal of Nephrology, 1985, 5, 236-242.	1.4	33
240	Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study. Journal of the American Society of Nephrology: JASN, 2005, 16, 1775-1780.	3.0	33
241	Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy. Diabetes Care, 2013, 36, 1489-1494.	4.3	33
242	Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. Nephrology Dialysis Transplantation, 2015, 30, iv86-iv95.	0.4	33
243	Preorganized macrocyclic ligands: a novel approach to functionalized hemispherands via aromatization. Journal of Organic Chemistry, 1987, 52, 4913-4921.	1.7	32
244	Quantification of renal low-molecular-weight protein handling in the intact rat. Kidney International, 1993, 43, 949-954.	2.6	32
245	Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 205-213.	1.0	32
246	Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nature Reviews Nephrology, 2012, 8, 691-699.	4.1	32
247	Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1568-1574.	2.2	32
248	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	2.6	32
249	Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid. Pharmaceutical Research, 1993, 10, 963-969.	1.7	31
250	ACE Inhibition Preserves Heparan Sulfate Proteoglycans in the Glomerular Basement Membrane of Rats with Established Adriamycin Nephropathy. Nephron Experimental Nephrology, 2000, 9, 21-27.	2.4	31
251	Chronic beta-blocker treatment in patients with advanced heart failure. International Journal of Cardiology, 2000, 73, 7-12.	0.8	31
252	The Geographical Distribution of Leadership in Globalized Clinical Trials. PLoS ONE, 2012, 7, e45984.	1.1	31

#	Article	IF	Citations
253	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Research and Care, 2014, 2, e000011.	1.2	31
254	Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension. Hypertension, 2015, 66, 563-570.	1.3	31
255	Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2119-2127.	2.2	31
256	Proteinuria and progression of renal disease. Current Opinion in Nephrology and Hypertension, 1997, 6, 133-140.	1.0	30
257	Metabolic syndrome: a fata morgana?. Nephrology Dialysis Transplantation, 2006, 22, 15-20.	0.4	30
258	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 925-933.	5.5	30
259	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148.	1.2	30
260	POTENTIALS AND LIMITATIONS OF THE LOW-MOLECULAR-WEIGHT PROTEIN LYSOZYME AS A CARRIER FOR RENAL DRUG TARGETING. Renal Failure, 2001, 23, 397-409.	0.8	29
261	Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II. Journal of Hypertension, 2004, 22, 2355-2361.	0.3	29
262	Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. American Journal of Physiology - Renal Physiology, 2010, 298, F625-F633.	1.3	29
263	Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrology Dialysis Transplantation, 2013, 28, 2260-2268.	0.4	29
264	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 2016, 23, 758-768.	0.8	29
265	Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. Journal of Pharmacological and Toxicological Methods, 1999, 41, 69-73.	0.3	28
266	Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. Nephrology Dialysis Transplantation, 2008, 24, 1182-1189.	0.4	28
267	Baseline characteristics and enrichment results from the <scp>SONAR</scp> trial. Diabetes, Obesity and Metabolism, 2018, 20, 1829-1835.	2.2	28
268	Angiotensin-converting enzyme gene I/D polymorphism and renal disease. Journal of Molecular Medicine, 1999, 77, 781-791.	1.7	27
269	Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotally nephrectomized rats. Journal of Hypertension, 2006, 24, 2215-2223.	0.3	27
270	Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. Journal of Hypertension, 2009, 27, 2321-2331.	0.3	27

#	Article	IF	Citations
271	Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. Heart, 2012, 98, 1348-1353.	1.2	27
272	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) â€“ Study Design and Baseline Characteristics. Kidney and Blood Pressure Research, 2018, 43, 181-190.	0.9	27
273	Individual Titration for Maximal Blockade of the Renin-Angiotensin System in Proteinuric Patients: A Feasible Strategy?. Journal of the American Society of Nephrology: JASN, 2005, 16, S53-S57.	3.0	26
274	Renal Damage after Myocardial Infarction Is Prevented by Renin-Angiotensin-Aldosterone-System Intervention. Journal of the American Society of Nephrology: JASN, 2006, 17, 3059-3066.	3.0	26
275	Drug targeting to the kidney with low-molecular-weight proteins. Advanced Drug Delivery Reviews, 1994, 14, 67-88.	6.6	25
276	Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta. British Journal of Pharmacology, 1999, 126, 1133-1138.	2.7	25
277	Role of the Endothelin-1 Gene Locus for Renal Impairment in the General Nondiabetic Population. Journal of the American Society of Nephrology: JASN, 2003, 14, 2596-2602.	3.0	25
278	Renoprotection by blocking the RAAS in diabetic nephropathyâ€"fact or fiction?. Nephrology Dialysis Transplantation, 2006, 21, 2354-2357.	0.4	25
279	Prolonged Frozen Storage of Urine Reduces the Value of Albuminuria for Mortality Prediction. Clinical Chemistry, 2007, 53, 153-154.	1.5	25
280	Change in Albuminuria Is Predictive of Cardiovascular Outcome in Normotensive Patients With Type 2 Diabetes and Microalbuminuria. Diabetes Care, 2007, 30, 3119-3121.	4.3	25
281	Differential Effects of Comorbidity on Antihypertensive and Glucose-Regulating Treatment in Diabetes Mellitus â€“ A Cohort Study. PLoS ONE, 2012, 7, e38707.	1.1	25
282	Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire. Drug Safety, 2013, 36, 765-777.	1.4	25
283	Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a populationâ€based cohort study. ESC Heart Failure, 2016, 3, 189-197.	1.4	25
284	Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney International, 2002, 61, 473-480.	2.6	24
285	High Dietary Sodium Blunts Effects of Angiotensin-converting Enzyme Inhibition on Vascular Angiotensin Iâ€"toâ€"Angiotensin II Conversion in Rats. Journal of Cardiovascular Pharmacology, 2003, 42, 601-606.	0.8	24
286	Approaches and methods in gene therapy for kidney disease. Journal of Pharmacological and Toxicological Methods, 2004, 50, 13-24.	0.3	24
287	Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study. Journal of Hypertension, 2004, 22, 1033-1037.	0.3	24
288	Microalbuminuria and C-reactive protein: Similar messengers of cardiovascular risk?. Current Hypertension Reports, 2005, 7, 379-384.	1.5	24

#	Article	IF	Citations
289	A Population-Based Screening for Microalbuminuria Among Relatives of CKD Patients: The Kidney Evaluation and Awareness Program in Sheffield (KEAPS). American Journal of Kidney Diseases, 2008, 52, 434-443.	2.1	24
290	Comparison of Midregional Proâ€“A-Type Natriuretic Peptide and the N-Terminal Proâ€“B-Type Natriuretic Peptide for Predicting Mortality and Cardiovascular Events. Clinical Chemistry, 2012, 58, 293-297.	1.5	24
291	An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection. Journal of Hypertension, 2012, 30, 1022-1028.	0.3	24
292	Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 490-498.	2.2	24
293	The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers. Clinical Pharmacology and Therapeutics, 2014, 95, 208-215.	2.3	24
294	Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: A clue to the mechanism of action. Clinical Science, 1991, 81, 367-372.	1.8	23
295	Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. Journal of Hypertension, 1995, 13, S53-S58.	0.3	23
296	Effect of Frozen Storage on Urinary Concentration of Kidney Damage Markers. American Journal of Kidney Diseases, 2012, 59, 586-589.	2.1	23
297	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. American Journal of Kidney Diseases, 2022, 79, 244-256.e1.	2.1	23
298	Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy. Pharmacoeconomics, 2006, 24, 523-535.	1.7	22
299	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. Journal of Hypertension, 2007, 25, 871-876.	0.3	22
300	Does the European Clinical Trials Directive really improve clinical trial approval time?. British Journal of Clinical Pharmacology, 2008, 66, 546-550.	1.1	22
301	Unmet Need in Renal Protection â€“ Do We Need a More Comprehensive Approach?. Contributions To Nephrology, 2011, 171, 157-160.	1.1	22
302	The blood pressure lowering potential of sulodexide â€“ a systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2015, 80, 1245-1253.	1.1	22
303	Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. Journal of Hypertension, 2015, 33, 2123-2132.	0.3	22
304	Variability in response to albuminuriaâ€lowering drugs: true or random?. British Journal of Clinical Pharmacology, 2017, 83, 1197-1204.	1.1	22
305	Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol. BMC Nephrology, 2020, 21, 242.	0.8	22
306	(Glyco)-protein drug carriers with an intrinsic therapeutic activity: The concept of dual targeting. Journal of Controlled Release, 1996, 39, 163-172.	4.8	21

#	Article	IF	Citations
307	A comparison of analytic procedures for measurement of fractional dextran clearances. Translational Research, 1998, 132, 390-403.	2.4	21
308	Drug Delivery to the Kidneys and the Bladder with the Low Molecular Weight Protein Lysozyme. Renal Failure, 1998, 20, 211-217.	0.8	21
309	Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. European Journal of Clinical Pharmacology, 1999, 54, 953-958.	0.8	21
310	Review: Intracellular angiotensin II: from myth to reality?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, 219-226.	1.0	21
311	Endothelial dysfunction and infarct-size relate to impaired EDHF response in rat experimental chronic heart failure. European Journal of Heart Failure, 2003, 5, 147-154.	2.9	21
312	A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. Health and Quality of Life Outcomes, 2011, 9, 83.	1.0	21
313	Gene therapy with adenovirusâ€delivered indoleamine 2,3â€dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat. Journal of Gene Medicine, 2011, 13, 373-381.	1.4	21
314	The End of Dual Therapy with Reninâ€“Angiotensinâ€“Aldosterone System Blockade?. New England Journal of Medicine, 2013, 369, 1960-1962.	13.9	21
315	Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrology Dialysis Transplantation, 2013, 28, 2841-2850.	0.4	21
316	Number and Frequency of Albuminuria Measurements in Clinical Trials in Diabetic Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 410-416.	2.2	21
317	Novel anti-inflammatory drugs for the treatment of diabetic kidney disease. Diabetologia, 2016, 59, 1621-1623.	2.9	21
318	Impaired Renal Vascular Response to a D1-Like Receptor Agonist But Not to an ACE Inhibitor in Conscious Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1999, 34, 191-198.	0.8	21
319	Functionalized Calixspherands: Synthesis and Peptide Coupling. Journal of Organic Chemistry, 1994, 59, 972-976.	1.7	20
320	Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998â€“2004: a longitudinal observational study. Cardiovascular Diabetology, 2007, 6, 25.	2.7	20
321	Albuminuria in heart failure: what do we really know?. Current Opinion in Cardiology, 2009, 24, 148-154.	0.8	20
322	Predictors of Progression in Albuminuria in the General Population: Results from the PREVEND Cohort. PLoS ONE, 2013, 8, e61119.	1.1	20
323	Coronary Myogenic Constriction Antagonizes EDHF-Mediated Dilation. Hypertension, 2003, 41, 912-918.	1.3	19
324	Biochemical risk markers: a novel area for better prediction of renal risk?. Nephrology Dialysis Transplantation, 2005, 20, 497-508.	0.4	19

#	Article	IF	Citations
325	High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested caseâ€“control study with confirmation in diabetes. Journal of Hypertension, 2013, 31, 805-812.	0.3	19
326	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 2014, 21, 434-441.	0.8	19
327	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the StudyÂofÂHeartÂand Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	2.1	19
328	Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study. American Journal of Kidney Diseases, 2016, 67, 70-78.	2.1	19
329	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes, Obesity and Metabolism, 2017, 19, 749-753.	2.2	19
330	Discontinuation of RAAS Inhibition in Children with Advanced CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 625-632.	2.2	19
331	Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 251-259.	2.2	19
332	Angiotensin converting enzyme inhibition improves diagnostic procedures for renovascular hypertension in dogs.. Hypertension, 1988, 12, 411-419.	1.3	18
333	Intracellular angiotensin II elicits Ca2+ increases in A7r5 vascular smooth muscle cells. European Journal of Pharmacology, 2001, 420, 9-18.	1.7	18
334	Albuminuria, Just a Marker for Cardiovascular Disease, Or Is It More?. Journal of the American Society of Nephrology: JASN, 2005, 16, 1883-1885.	3.0	18
335	Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, S10-S14.	3.3	18
336	Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. Nephrology Dialysis Transplantation, 2013, 28, 706-715.	0.4	18
337	Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. CKJ: Clinical Kidney Journal, 2021, 14, 1396-1402.	1.4	18
338	Atrial Natriuretic Peptide-Induced Decreases in Renal Blood Flow in Man: Implications for the Natriuretic Mechanism. Clinical Science, 1989, 77, 55-60.	1.8	17
339	Renal specific delivery of sulfamethoxazole in the rat by coupling to the low molecular weight protein lysozyme via an acid-sensitive linker. International Journal of Pharmaceutics, 1992, 80, R15-R19.	2.6	17
340	Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. Kidney International, 2003, 63, 64-71.	2.6	17
341	Should albuminuria be a therapeutic target in patients with hypertension and diabetes?. American Journal of Hypertension, 2004, 17, S11-S15.	1.0	17
342	Adenovirusâ€mediated interleukinâ€13 gene therapy attenuates acute kidney allograft injury. Journal of Gene Medicine, 2007, 9, 1024-1032.	1.4	17

#	Article	IF	Citations
343	Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus. Diabetic Medicine, 2009, 26, 556-559.	1.2	17
344	Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events. Nephrology Dialysis Transplantation, 2013, 28, 2805-2815.	0.4	17
345	Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database. BMJ Quality and Safety, 2013, 22, 339-347.	1.8	17
346	A novel approach for establishing cardiovascular drug efficacy. Nature Reviews Drug Discovery, 2014, 13, 942-942.	21.5	17
347	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. Diabetes and Vascular Disease Research, 2019, 16, 47-56.	0.9	17
348	Chronic Angiotensin II Infusion But Not Bradykinin Blockade Abolishes the Antiproteinuric Response to Angiotensin-Converting Enzyme Inhibition in Established Adriamycin Nephrosis. Journal of the American Society of Nephrology: JASN, 2000, 11, 490-496.	3.0	17
349	Highly sensitive measurement of indomethacin using a high-performance liquid chromatographic technique combined with post-column in-line hydrolysis. Biomedical Applications, 1986, 380, 157-162.	1.7	16
350	A method for accurate measurement of GFR in conscious, spontaneously voiding rats. Kidney International, 1997, 52, 244-247.	2.6	16
351	Renoprotection with and without blood pressure reduction. Kidney International, 2005, 67, S54-S59.	2.6	16
352	Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors. Nephrology Dialysis Transplantation, 2010, 25, 3560-3568.	0.4	16
353	Improving clinical trial efficiency by biomarker-guided patient selection. Trials, 2014, 15, 103.	0.7	16
354	Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. Nephrology Dialysis Transplantation, 2016, 31, 1471-1477.	0.4	16
355	Prevalence and distribution of (micro)albuminuria in toddlers. Nephrology Dialysis Transplantation, 2016, 31, 1686-1692.	0.4	16
356	Renal and Systemic Effects of the Renin Inhibitor Remikiren in Patients with Essential Hypertension. Journal of Cardiovascular Pharmacology, 1995, 26, 39-45.	0.8	15
357	Urine collection in the freely moving rat: Reliability for measurement of short-term renal effects. Journal of Pharmacological and Toxicological Methods, 1997, 38, 47-51.	0.3	15
358	Targeting of Doxorubicin to the Urinary Bladder of the Rat Shows Increased Cytotoxicity in the Bladder Urine Combined With An Absence of Renal Toxicity. Journal of Drug Targeting, 2002, 10, 81-89.	2.1	15
359	Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 106-112.	1.0	15
360	Does Angiotensin (1-7) Contribute to the Antiproteinuric Effect of ACE-inhibitors?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, 96-101.	1.0	15

#	Article	IF	Citations
361	Endothelial Function Predicts the Development of Renal Damage after Combined Nephrectomy and Myocardial Infarction. Journal of the American Society of Nephrology: JASN, 2006, 17, S49-S52.	3.0	15
362	Targeting Proteinuria as a Valid Surrogate for Individualized Kidney Protective Therapy. American Journal of Kidney Diseases, 2008, 51, 713-716.	2.1	15
363	ESRD After Heart Failure, Myocardial Infarction, or Stroke in TypeÂ2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 2017, 70, 522-531.	2.1	15
364	Does <scp>SGLT</scp>2 inhibition with dapagliflozin overcome individual therapy resistance to <scp>RAAS</scp> inhibition?. Diabetes, Obesity and Metabolism, 2018, 20, 224-227.	2.2	15
365	Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2020, 31, 2446-2456.	3.0	15
366	The antihypertensive and renal effects of angiotensin II receptor antagonists: remaining questions. Current Opinion in Nephrology and Hypertension, 2000, 9, 57-61.	1.0	14
367	Renoprotection: A Matter of Blood Pressure Reduction or Agent-Characteristics?. Journal of the American Society of Nephrology: JASN, 2002, 13, S202-S207.	3.0	14
368	Physiciansâ€™ attitudes towards treatment guidelines: differences between teaching and nonteaching hospitals. European Journal of Clinical Pharmacology, 2006, 62, 129-133.	0.8	14
369	Omicsâ€“Bioinformatics in the Context of Clinical Data. Methods in Molecular Biology, 2011, 719, 479-497.	0.4	14
370	Association Between Performance Measures and Glycemic Control Among Patients With Diabetes in a Community-wide Primary Care Cohort. Medical Care, 2013, 51, 172-179.	1.1	14
371	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes, Obesity and Metabolism, 2020, 22, 530-539.	2.2	14
372	Nephroptosis and Kidney Function. Nephron, 1978, 22, 366-373.	0.9	13
373	Renal targeting of a non-steroidal anti-inflammatory drug: effects on renal prostaglandin synthesis in the rat. Clinical Science, 1998, 95, 603-609.	1.8	13
374	Does comorbidity explain trends in prescribing of newer antihypertensive agents?. Journal of Hypertension, 2004, 22, 2209-2215.	0.3	13
375	Enhanced transduction of fibroblasts in transplanted kidney with an adenovirus having an RGD motif in the HI loop. Kidney International, 2006, 69, 45-52.	2.6	13
376	Claims in advertisements for antihypertensive drugs in a Dutch medical journal. Journal of Hypertension, 2007, 25, 713-722.	0.3	13
377	Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to aNalyse Type 2 diabetes Treatment (GIANTT) observational study. Pharmacoepidemiology and Drug Safety, 2010, 19, 1078-1086.	0.9	13
378	Comparing Adverse Event Rates of Oral Blood Glucose-Lowering Drugs Reported by Patients and Healthcare Providers. Drug Safety, 2011, 34, 1191-1202.	1.4	13

#	Article	IF	Citations
379	Determining the optimal dose of atrasentan by evaluating the exposureâ€response relationships of albuminuria and bodyweight. Diabetes, Obesity and Metabolism, 2018, 20, 2019-2022.	2.2	13
380	Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia, 2018, 61, 581-588.	2.9	13
381	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	2.6	13
382	Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. Cardiovascular Research, 2022, 118, 1103-1114.	1.8	13
383	Do Treatment Quality Indicators Predict Cardiovascular Outcomes in Patients with Diabetes?. PLoS ONE, 2013, 8, e78821.	1.1	13
384	Proteinuria: A risk factor for pregnancy-related renal function decline in primary glomerular disease?. American Journal of Kidney Diseases, 1995, 26, 187-192.	2.1	12
385	Normalization of aortic function during arousal episodes in the hibernating ground squirrel. Life Sciences, 2002, 70, 2071-2083.	2.0	12
386	Renoprotective therapy: is it blood pressure or albuminuria that matters?. Lancet, The, 2005, 365, 913-914.	6.3	12
387	Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 217-224.	1.0	12
388	Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease. Seminars in Nephrology, 2001, 21, 580-592.	0.6	12
389	Relief of Renal Artery Stenosis: A Tool to Improve or Preserve Renal Function in Renovascular Disease?. Nephrology Dialysis Transplantation, 1990, 5, 481-488.	0.4	11
390	Discordant effects of enalapril and lisinopril on systemic and renal hemodynamics. Clinical Pharmacology and Therapeutics, 1994, 56, 647-658.	2.3	11
391	Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. Kidney International, 1996, 49, 174-180.	2.6	11
392	Targeting of Captopril to the Kidney Reduces Renal Angiotensin-Converting Enzyme Activity without Affecting Systemic Blood Pressure. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 1139-1143.	1.3	11
393	How to measure the prevalence of microalbuminuria in relation to age and gender?. American Journal of Kidney Diseases, 2002, 40, 436-437.	2.1	11
394	Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 197-202.	1.0	11
395	Low Sodium Modifies the Vascular Effects of Angiotensin-Converting Enzyme Inhibitor Therapy in Healthy Rats. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1183-1189.	1.3	11
396	Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney International, 2005, 67, S52-S54.	2.6	11

#	Article	IF	Citations
397	Immune modulation and graft protection by gene therapy in kidney transplantation. European Journal of Pharmacology, 2008, 585, 261-269.	1.7	11
398	Impact of the Preintervention Rate of Renal Function Decline on Outcome of Renoprotective Intervention. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 54-60.	2.2	11
399	Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system. Kidney International, 2008, 74, 377-383.	2.6	11
400	The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation, 2009, 24, 2975-2983.	0.4	11
401	Dual Renin-Angiotensin System Blockade and Kidney Disease. Journal of the American College of Cardiology, 2009, 54, 278-279.	1.2	11
402	CKD Treatment: Time to Alter the Focus to Albuminuria?. Advances in Chronic Kidney Disease, 2011, 18, 222-223.	0.6	11
403	ONTARGET still OFF-TARGET?. Circulation, 2011, 123, 1049-1051.	1.6	11
404	Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study. Health and Quality of Life Outcomes, 2014, 12, 103.	1.0	11
405	The Role of Patientsâ€™ Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. PLoS ONE, 2015, 10, e0139755.	1.1	11
406	The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders. PLoS ONE, 2014, 9, e108722.	1.1	11
407	Renin Inhibition Improves Pressure Natriuresis in Essential Hypertension. Journal of the American Society of Nephrology: JASN, 2000, 11, 1813-1818.	3.0	11
408	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1824-1832.	2.2	11
409	Unilateral Renal Parenchymal Disease with Contralateral Renal Artery Stenosis of the Fibrodysplasia Type. Annals of Internal Medicine, 1989, 110, 437.	2.0	10
410	The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment. Metabolism: Clinical and Experimental, 1996, 45, 723-730.	1.5	10
411	Letters. Diabetic Medicine, 2000, 17, 550-552.	1.2	10
412	Direct interaction between the sympathetic and reninâ€“angiotensin system in myocardial tissue: a microdialysis study in anaesthetised rats. Journal of the Autonomic Nervous System, 2000, 78, 117-121.	1.9	10
413	Regulation of [Ca2+]i homeostasis in MRP1 overexpressing cells. FEBS Letters, 2000, 474, 107-110.	1.3	10
414	Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats. British Journal of Pharmacology, 2002, 136, 1107-1116.	2.7	10

#	Article	IF	Citations
415	Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 27-32.	1.0	10
416	Urinary pH affects albumin concentrations after prolonged frozen storage. Nephrology Dialysis Transplantation, 2007, 22, 3670-3670.	0.4	10
417	Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes. Diabetes Care, 2008, 31, S190-S193.	4.3	10
418	Renal failure induces telomere shortening in the rat heart. Netherlands Heart Journal, 2009, 17, 190-194.	0.3	10
419	Rebuttal: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial. American Journal of Nephrology, 2010, 31, 466-467.	1.4	10
420	Renal end points in clinical trials of kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 1.	1.0	10
421	Blood pressureâ€lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies. British Journal of Clinical Pharmacology, 2016, 82, 1351-1357.	1.1	10
422	Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 1377-1383.	2.2	10
423	Nâ€terminal proâ€brain natriuretic peptide (NTâ€proBNP) predicts the cardioâ€renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes, Obesity and Metabolism, 2018, 20, 2899-2904.	2.2	10
424	Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy. Nephrology Dialysis Transplantation, 2020, 35, ii38-ii42.	0.4	10
425	Interâ€individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the <scp>SONAR</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 561-568.	2.2	10
426	Endothelin Receptor Antagonists for Kidney Protection. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 908-910.	2.2	10
427	Clearance of indometacin occurs predominantly by renal glucuronidation. Pharmaceutisch Weekblad, 1992, 14, 191-195.	0.7	9
428	Sample Dilution: A Methodological Pitfall in the Measurement of Tissue but not Serum Ace-Activity. Journal of Pharmacological and Toxicological Methods, 1998, 39, 45-49.	0.3	9
429	Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease: the potential of exploring the mechanisms of response variability. Current Opinion in Nephrology and Hypertension, 2002, 11, 135-140.	1.0	9
430	Clinical Trial in Nephrology at Hard End Point?. Journal of the American Society of Nephrology: JASN, 2004, 15, 506-508.	3.0	9
431	Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage. Nephrology Dialysis Transplantation, 2008, 24, 413-420.	0.4	9
432	Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohort. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1381-90.	1.4	9

#	Article	IF	Citations
433	Renal trials in diabetes need a platform: time for a global approach?. Lancet Diabetes and Endocrinology,the, 2018, 6, 356-358.	5.5	9
434	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 2900-2911.	3.0	9
435	Mechanism of the Antiproteinuric Effect of Angiotensin-Converting Enzyme Inhibition1. Contributions To Nephrology, 1990, 83, 160-165.	1.1	8
436	Atrial natriuretic factor influences renal diurnal rhythm in essential hypertension.. Hypertension, 1992, 20, 80-84.	1.3	8
437	Drug-induced changes in renal hippurate clearance as a measure of renal blood flow. Kidney International, 1995, 48, 1617-1623.	2.6	8
438	Renal disease: a common and a silent killer. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, S27-S35.	3.3	8
439	Albuminuria: What can we expect from the determination of nonimmunoreactive albumin?. Current Hypertension Reports, 2009, 11, 111-117.	1.5	8
440	The validity of a patient-reported adverse drug event questionnaire using different recall periods. Quality of Life Research, 2014, 23, 2439-2445.	1.5	8
441	Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 3405-3412.	3.0	8
442	Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation, 2019, 34, 1699-1706.	0.4	8
443	The future of Diabetic Kidney Disease management: reducing the unmet need. Journal of Nephrology, 2020, 33, 1163-1169.	0.9	8
444	The Antiproteinuric Effect of Angiotensin-Converting-Enzyme Inhibitors in Human Renal Disease. , 1991, , 95-113.		8
445	Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. Kidney International, 1999, 56, 42-46.	2.6	8
446	Blood pressure response to enalaprilic acid in essential hypertension: Dose-response and effect of pre-treatment with furosemide. European Journal of Clinical Pharmacology, 1985, 29, 9-15.	0.8	7
447	The Antiproteinuric Effects of Blood Pressure-Lowering Agents: Differences Between Nondiabetics and Diabetics. Journal of Cardiovascular Pharmacology, 1992, 19, S28-S32.	0.8	7
448	Intracellular angiotensin II inhibits heterologous receptor stimulated Ca2+ entry. Life Sciences, 2001, 70, 171-180.	2.0	7
449	Does a low-salt diet exert a protective effect on endothelial function in normal rats?. Translational Research, 2001, 138, 200-205.	2.4	7
450	The COOPERATE trial. Lancet, The, 2003, 361, 1055-1056.	6.3	7

#	Article	IF	Citations
451	A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Current Medical Research and Opinion, 2006, 22, 2095-2100.	0.9	7
452	Drug Dosing for Renoprotection. Journal of the American Society of Nephrology: JASN, 2009, 20, 688-689.	3.0	7
453	Comparison of urine collection methods for albuminuria assessment in young children. Clinica Chimica Acta, 2016, 458, 120-123.	0.5	7
454	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1804-1813.	2.2	7
455	Treating diabetic complications; from large randomized clinical trials to precision medicine. Diabetes, Obesity and Metabolism, 2018, 20, 3-5.	2.2	7
456	Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. European Journal of Clinical Investigation, 1999, 29, 1019-1026.	1.7	6
457	The Abnormal Renal Vasodilator Response to D1-Like Receptor Stimulation in Conscious SHR Can Be Normalized by AT1 Blockade. Journal of Cardiovascular Pharmacology, 2004, 44, 571-576.	0.8	6
458	Uptake of angiotensin II receptor blockers in the treatment of hypertension. European Journal of Clinical Pharmacology, 2005, 61, 461-466.	0.8	6
459	Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats. European Journal of Pharmacology, 2008, 580, 231-240.	1.7	6
460	Defining the optimal dose of a new drug: a crucial decision. Nature Reviews Nephrology, 2009, 5, 498-500.	4.1	6
461	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. Drugs in R and D, 2017, 17, 441-448.	1.1	6
462	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1652-1659.	2.2	6
463	Reasons for hospitalizations in patients with type 2 diabetes in the <scp>CANVAS</scp> programme: A secondary analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2707-2715.	2.2	6
464	Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentanâ€™s Efficacy: A Post Hoc Analysis from the SONAR Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 2731-2734.	3.0	6
465	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. Diabetologia, 2021, 64, 2402-2414.	2.9	6
466	Pharmacological zero for electromagnetic renal blood flow measurement. Pflugers Archiv European Journal of Physiology, 1985, 403, 220-221.	1.3	5
467	Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. Kidney International, 1999, 56, S42-S46.	2.6	5
468	The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review. British Journal of Clinical Pharmacology, 2002, 53, 549P-550P.	1.1	5

#	Article	IF	Citations
469	Is the randomized controlled drug trial in Europe lagging behind the USA?. British Journal of Clinical Pharmacology, 2008, 66, 774-780.	1.1	5
470	High serum potassium levels after losartan can reflect more severe renal disease. Reply to GonÃ§alves AR, El Nahas AM [letter]. Diabetologia, 2011, 54, 2965-2967.	2.9	5
471	Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703-709. Diabetes Care, 2011, 34, e124-124.	4.3	5
472	Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats. American Journal of Physiology - Renal Physiology, 2016, 310, F1047-F1053.	1.3	5
473	Individual Atrasentan Exposure is Associated With Longâ€term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacology and Therapeutics, 2021, 109, 1631-1638.	2.3	5
474	Canagliflozin, serum magnesium and cardiovascular outcomesâ€"Analysis from the CANVAS Program. Endocrinology, Diabetes and Metabolism, 2021, 4, e00247.	1.0	5
475	Direct Vasodilating Effects of the New Dopaminergic Agonist Z1046 in Human Arteries. Journal of Cardiovascular Pharmacology, 2000, 35, 581-585.	0.8	5
476	Indomethacin secretion in the isolated perfused proximal straight rabbit tubule. Evidence for two parallel transport mechanisms.. Journal of Clinical Investigation, 1988, 81, 1585-1592.	3.9	5
477	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes and Metabolism, 2022, 48, 101331.	1.4	5
478	How to measure the prevalence of microalbuminuria in relation to age and gender?. American Journal of Kidney Diseases, 2002, 40, 436-7; author reply 437.	2.1	5
479	Quantification of Renal Low-Molecular-Weight Protein Degradation in the Intact Rat. Contributions To Nephrology, 1993, 101, 78-84.	1.1	4
480	Role of proteinuria in the regulation of renal renin-angiotensin system components in unilateral proteinuric rats. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 38-42.	1.0	4
481	Beneficial effects of add-on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril. European Journal of Heart Failure, 2005, 7, 1085-1094.	2.9	4
482	Letter Regarding Article by Klausen et al, â€œVery Low Levels of Microalbuminuria Are Associated With Increased Risk of Coronary Heart Disease and Death Independently of Renal Function, Hypertension, and Diabetesâ€• Circulation, 2005, 111, e110-1; author reply e110-1.	1.6	4
483	Paricalcitol for reduction of albuminuria in diabetes â€“ Authors' reply. Lancet, The, 2011, 377, 636-637.	6.3	4
484	Drug-Induced Changes in Risk/Biomarkers and Their Relationship with Renal and Cardiovascular Long-Term Outcome in Patients with Diabetes. Clinical Chemistry, 2011, 57, 186-195.	1.5	4
485	Dual RAAS blockade has dual effects on outcome. Nature Reviews Endocrinology, 2013, 9, 261-263.	4.3	4
486	Comparison of exposure response relationship of atrasentan between <scp>N</scp>orth <scp>A</scp>merican and <scp>A</scp>sian populations. Diabetes, Obesity and Metabolism, 2017, 19, 545-552.	2.2	4

#	Article	IF	Citations
487	Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1595-1600.	2.2	4
488	How to measure and monitor albuminuria in healthy toddlers?. PLoS ONE, 2018, 13, e0199309.	1.1	4
489	Renal function as a predictor of prognosis in chronic heart failure. Heart Failure Monitor, 2002, 2, 78-84.	0.7	4
490	Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With IncidentÂHeartÂFailure. JACC: Heart Failure, 2022, 10, 498-507.	1.9	4
491	Unilateral Kidney Blood Flow Measurement Using the 81Rb/81mKr Ratio. Contributions To Nephrology, 1978, 11, 67-72.	1.1	3
492	Semi-micro method for the determination of cation flux rate constants in erythrocytes. Clinica Chimica Acta, 1985, 150, 137-149.	0.5	3
493	Angiotensin converting enzyme inhibition induces alterations to hippuran renography despite unchanged ipsilateral renal blood flow in conscious two-kidney, one clip Goldblatt hypertensive dogs. Journal of Hypertension, 1988, 6, S455-457.	0.3	3
494	A general method for the determination of the kinetic stability of macrocyclic alkali-metal complexes with rates of decomplexation below 10â€“3sâ€“1. Journal of the Chemical Society Perkin Transactions II, 1994, , 11-14.	0.9	3
495	Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition?. Nephrology Dialysis Transplantation, 2002, 17, 793-797.	0.4	3
496	Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2003, 4, 1543-1550.	0.9	3
497	Detecting and managing patients with type 2 diabetic kidney disease: Proteinuria and cardiovascular disease. Kidney International, 2004, 66, S97-S98.	2.6	3
498	Future and Novel Compounds in theÂTreatment of Diabetic Nephropathy. , 2019, , 515-539.		3
499	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney International, 2000, 57, 32-37.	2.6	3
500	Renal hemodynamics in human hypertension. Advances in Organ Biology, 2000, 9, 369-382.	0.1	2
501	D2-Like Receptor Stimulation Decreases Effective Renal Plasma Flow and Glomerular Filtration Rate in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2002, 40, 35-42.	0.8	2
502	Can angiotensin II be used for renoprotection?. Kidney International, 2002, 61, 1176-1177.	2.6	2
503	Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat. Clinical Science, 2003, 105, 51-57.	1.8	2
504	Reducing cardiovascular risk: protecting the kidney. European Heart Journal Supplements, 2009, 11, F39-F46.	0.0	2

#	Article	IF	Citations
505	Do diabetic kidneys deserve a lifestyle change?. Lancet Diabetes and Endocrinology,the, 2014, 2, 769-770.	5.5	2
506	Are Post-Trial Observational Studies Useful?. Journal of the American Society of Nephrology: JASN, 2014, 25, 2148-2150.	3.0	2
507	Albuminuria. , 2015, , 663-673.		2
508	EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL. Journal of the American College of Cardiology, 2020, 75, 215.	1.2	2
509	The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. Kidney International, 2021, 99, 551-554.	2.6	2
510	A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882097419.	1.4	2
511	27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease. Diabetes, 2020, 69, .	0.3	2
512	A new constrictor device for external induction of a long-term stable and irreversible renal artery stenosis in the dog. Pflugers Archiv European Journal of Physiology, 1988, 411, 688-691.	1.3	1
513	Micro-HPLC and transfer techniques for directly measuring drug (indomethacin) transport across the isolated perfused renal proximal straight tubule. Journal of Pharmacological Methods, 1988, 19, 275-282.	0.7	1
514	Human plasma contains low molecular weight factors which stimulate active sodium transport in erythrocytes. Clinica Chimica Acta, 1989, 179, 133-142.	0.5	1
515	Accelerated progression of renal function loss after two pregnancies in a patient with proteinuria. Lancet, The, 1992, 340, 183.	6.3	1
516	Differences in erythrocyte sodium transport between human plasma and artificial medium: the role and character of sodium efflux and influx stimulating plasma factors. Clinica Chimica Acta, 1992, 213, 61-73.	0.5	1
517	Influence of Anaesthesia on Renal Hippurate Handling during Angiotensin-Converting Enzyme Inhibition in Unilateral Renal Artery Stenosis. American Journal of Nephrology, 1992, 12, 474-476.	1.4	1
518	Determination of dopaminergic prodrugs by high-performance liquid chromatography followed by post-column ion-pair extraction. Biomedical Applications, 1997, 693, 484-488.	1.7	1
519	Can Continuous Intraperitoneal Infusion of¹²⁵I-Iothalamate and¹³¹I-Hippuran Be Used for Measurement of GFR in Conscious Rats?. Renal Failure, 1998, 20, 249-255.	0.8	1
520	Statins. Journal of Hypertension, 2002, 20, 2351-2353.	0.3	1
521	Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy. , 2014, , 222-234.		1
522	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€"The Berlin Roadmap. Kidney International Reports, 2016, 1, 327-339.	0.4	1

#	Article	IF	Citations
523	Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin. Diabetes, Obesity and Metabolism, 2019, 21, 2635-2642.	2.2	1
524	Atrasentan in patients with diabetes and chronic kidney disease â€“ Authors' reply. Lancet, The, 2020, 395, 270.	6.3	1
525	Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD. CKJ: Clinical Kidney Journal, 2021, 14, 2170-2176.	1.4	1
526	Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting. Frontiers in Pharmacology, 2021, 12, 662642.	1.6	1
527	Angiotensin-converting enzyme gene I/D polymorphism and renal disease. , 1999, 77, 781.		1
528	Proteinuria. Obstetrical and Gynecological Survey, 1996, 51, 145-146.	0.2	1
529	A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters. , 2000, , 587-600.		1
530	A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters. , 1998, , 585-595.		1
531	Consistent Outcomes with Canagliflozin (CANA) in Patients with Type 2 Diabetes across Geographic Regionsâ€"Results from the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. Diabetes, 2018, 67, 1193-P.	0.3	1
532	1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program. Diabetes, 2019, 68, .	0.3	1
533	Rationale, Design and Baseline Characteristics of the Effect of Canagliflozin in Type 2 Diabetic Patients with Microalbuminuria in Japanese Population (<scp>CANPIONE</scp>) study. Diabetes, Obesity and Metabolism, 2022, , .	2.2	1
534	Management of chronic renal failure. Current Opinion in Nephrology and Hypertension, 1992, 1, 116-123.	1.0	0
535	Have Rational Therapeutic Principles Emerged in Treating Hypertension in Chronic Renal Failure?. American Journal of Kidney Diseases, 1993, 21, 108-112.	2.1	0
536	CV4 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA. Value in Health, 2003, 6, 615-616.	0.1	0
537	Best practice of hypertensive patietns with kidney disease. British Journal of Hospital Medicine, 2003, 64, 96-100.	0.3	0
538	Gansevoort et al. Respond to â€œUsing Measures of Albumin Excretionâ€• American Journal of Epidemiology, 2006, 164, 731-732.	1.6	0
539	ROADMAP: the road to renoprotection?. Nature Reviews Nephrology, 2011, 7, 427-428.	4.1	0
540	PS12 - 60. Not all performance measures of diabetes management predict better glycemic control. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 140-141.	0.0	0

#	Article	IF	Citations
541	PS12 Contâ€™d - 62. Prescribing of aliskiren in practice: findings from the GIANTT diabetes. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 142-143.	0.0	0
542	PS3 - 5. Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 142-142.	0.0	0
543	PS11 - 1. Longitudinal eGFR trajectories in patients with type 2 diabetes. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 162-162.	0.0	0
544	The Authors Reply:. Kidney International, 2014, 86, 1270.	2.6	0
545	New renal guidelines; is more better?. Nephrology Dialysis Transplantation, 2014, 29, 720-721.	0.4	0
546	FP272A PANEL OF NOVEL BIOMARKERS REPRESENTING DIFFERENT DISEASE PATHWAYS IMPROVES PREDICTION OF RENAL FUNCTION DECLINE IN TYPE 2 DIABETES. Nephrology Dialysis Transplantation, 2015, 30, iii158-iii158.	0.4	0
547	The paradox created by commenting on large clinical trial results. Diabetes, Obesity and Metabolism, 2015, 17, 1-2.	2.2	0
548	Pathophysiology of Proteinuria: Albuminuria as a Target for Treatment. , 2020, , 211-224.		0
549	P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
550	P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
551	P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
552	Reply. JACC: Heart Failure, 2020, 8, 427.	1.9	0
553	129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial. Diabetes, 2021, 70, 129-LB.	0.3	0
554	133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE. Diabetes, 2021, 70, 133-LB.	0.3	0
555	131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial. Diabetes, 2021, 70, 131-LB.	0.3	0
556	How to Attain Optimal Antiproteinuric Dose of Losartan in Non-Diabetic Patients with Nephrotic Range Proteinuria. , 2002, , 69-73.		0
557	Increased Levels of Urinary Albumin: A Cardiovascular Risk Factor and a Target for Treatment. , 2010, , 105-116.		0
558	A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters. , 1996, , 551-559.		0

#	Article	IF	Citations
559	Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. Diabetes, 2018, 67, 1191-P.	0.3	0
560	Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program Irrespective of Baseline (BL) Body Mass Index (BMI). Diabetes, 2018, 67, .	0.3	0
561	(Clinical) Trial and Error in Diabetic Nephropathy. , 2019, , 415-431.		0
562	1203-P: Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program. Diabetes, 2019, 68, .	0.3	0
563	2-OR: Impact of N Terminal Pro B-Type Natriuretic Peptide and High Sensitivity Cardiac Troponin on the Prediction of Death and Cardiovascular Events in High-Risk Patients with Type 2 Diabetes. Diabetes, 2020, 69, .	0.3	0
564	1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD). Diabetes, 2020, 69, .	0.3	0
565	1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial. Diabetes, 2020, 69, .	0.3	0
566	26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE. Diabetes, 2020, 69, .	0.3	0
567	Best practice for hypertensive patients with kidney disease. British Journal of Hospital Medicine, 2003, 64, 96-100.	0.3	0